News & Events about Kymera Therapeutics Inc.
WATERTOWN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the Company will present at the 41st Annual J.P...
Kymera Therapeutics, Inc. (NASDAQ:KYMR Get Rating) Director Bruce Booth sold 378,966 shares of the companys stock in a transaction dated Wednesday, December 14th. The shares were sold at an average price of $31.37, for a total transaction of $11,888,163.42. Following the completion of...
Kymera Therapeutics, Inc. (NASDAQ:KYMR Get Rating) major shareholder Venture Fund X. L.P. Atlas sold 296,077 shares of the stock in a transaction on Wednesday, December 14th. The stock was sold at an average price of $31.37, for a total transaction of $9,287,935.49. Following the sale, the ...
Kymera Therapeutics, Inc. (NASDAQ:KYMR Get Rating) major shareholder Venture Fund X. L.P. Atlas sold 296,077 shares of the stock in a transaction on Wednesday, December 14th. The stock was sold at an average price of $31.37, for a total transaction of $9,287,935.49. Following the sale, the insider ...
Kymera Therapeutics, Inc. (NASDAQ:KYMR Get Rating) shares gapped up before the market opened on Wednesday after SVB Leerink raised their price target on the stock from $26.00 to $31.00. The stock had previously closed at $25.85, but opened at $33.46. SVB Leerink currently has a market perform rating...